News

Osmol Therapeutics Announces Appointment of Teresa Bitetti, President, Global Oncology Business Unit at Takeda Pharmaceuticals, to the Board of Directors

Osmol Therapeutics, a privately held biopharmaceutical company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN), today announced that Teresa Bitetti, President of the Global Oncology Business Unit at Takeda Pharmaceutical Company Ltd., has joined the Board of Directors of Osmol Therapeutics.

Osmol Therapeutics Announces Closing of Series A-1 Funding to Advance the Clinical Development of the First Therapy to Prevent Chemotherapy-induced Neuropathy

Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1 clinical study is projected to begin in 2022. There are currently no Food and Drug Administration (FDA) approved therapies for the prevention or treatment of CIPN, a debilitating condition resulting from the off-target toxicity of many chemotherapy treatments.

CEO of Osmol Therapeutics Leads Virtual Charge to Develop Ground-Breaking Treatment for Prevent Chemo Side-Effects

Bob Linke, CEO of Osmol, was interviewed for the CEO Leadership Series sponsored by Ashton-Tweed, a life sciences executive search firm Mr. Linke discusses OSM-0205, the company’s ground-breaking CIPN treatment and managing a virtual team during the COVID-19 pandemic.

Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy

Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1 clinical study is projected to begin in 2022. There are currently no Food and Drug Administration (FDA) approved therapies for the prevention or treatment of CIPN, a debilitating condition resulting from the off-target toxicity of many chemotherapy treatments.

BioWorld News to Note for May 13, 2021

Osmol Therapeutics Inc., of New Haven, Conn., said it initiated IND-enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase I study is projected by the company to begin in 2022.